WILMINGTON, MA – Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that it has received orders for its Quantum Sniffer(TM) QS-H150 portable explosives trace detection (ETD) device which total approximately $700,000. The orders will be delivered into China, Spain, the United Kingdom and Russia, and represent a mixture of new and repeat customers. The QS-H150 will be used in a variety of security applications including airport passenger screening and port security.

“We are beginning to reap the benefits of our focus on expanding sales, marketing, and distribution channels internationally as we penetrate into new markets. Equally pleasing are the repeat orders from existing customers, proof of the advantages of the Quantum Sniffer,” stated Bruce Bower, Sr. Vice President of Sales and Marketing for Implant Sciences.

“Our non-contact, non-radioactive explosives trace detector allows for non-intrusive, dignified and efficient passenger screening, eliminating the embarrassment and health concerns associated with other passenger screening methods,” stated Glenn D. Bolduc, CEO of Implant Sciences. “Customers continue to select our products because of their effectiveness in real world situations and we are proud to assist those in combating terrorism worldwide.”

About the Quantum Sniffer QS-H150

The QS-H150 Quantum Sniffer is a hand-held explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability and extremely low total cost of ownership.

About the Quantum Sniffer QS-B220

The Quantum Sniffer QS-B220, introduced in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management’s current expectations and assumptions which could differ materially from the forward-looking statements.